Abagovomab

Published

dm+d

Unassigned

New Medicines

AbagovomabOvarian cancer

Information

Abagovomab
New molecular entity
Menarini
Menarini

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Mar 15: No longer listed in company pipeline therefore assume discontinued.

Category

An anti-idiotypic monoclonal antibody that mimics a specific epitope on the tumour-associated antigen, CA125.
The UK incidence of OC is 21 per 100,000 people. 75% have advanced disease and up to 80% respond to first-line platinum chemotherapy; of these 55-75% relapse within 2 years.
Ovarian cancer
maintenance therapy after first-line chemotherapy
Subcutaneous